Federal Register #FDA-2026-N-7542

FDA Public Hearing and Request for Comments on Future Therapeutic Use of Psychedelic Drugs

This FDA public hearing is focused on gathering input on the future therapeutic use of psychedelic drugs in supervised and supportive settings. - Hosted by the Food and Drug Administration (FDA), Department of Health and Human Services - Seeks public and stakeholder comments on: - Provider training and credentialing requirements - Patient safety and risk mitigation strategies - Access and equity considerations for patients - Best practices for data collection and standardization - No products, vendors, or OEMs are being solicited - The event is intended to inform regulatory and policy decisions regarding psychedelic drug therapies - Stakeholder engagement is emphasized, including participation from healthcare providers, researchers, and the public - No procurement, contract, or purchase is associated with this opportunity

Description

The Food and Drug Administration (FDA) is announcing a public hearing to gather feedback on the potential future therapeutic use of psychedelic drugs in supervised and supportive settings. The hearing will be held in a hybrid format on September 14, 2026, and aims to discuss provider training, patient safety, access considerations, and best practices for data collection. Registration is required by August 21, 2026, and comments can be submitted until October 5, 2026. The FDA seeks input to inform coordinated federal efforts and regulatory considerations related to psychedelic drug therapies.

View original listing